Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of HSK21542 injection for prevention of chemotherapy-induced nausea and vomiting
CTR20253096Phase 2Active
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of hsk21542 in chemotherapy-induced nausea and vomiting (CINV), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started Aug 2025; status: active.
02
Drugs
hsk21542
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on CTR20253096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253096.